Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 9/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | GRM8 | O00222 | 2/20 | 0.37 |
| ▸ | GRM6 | O15303 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5586474 | 0.80 | — | — | |
| SCHEMBL9246797 | 0.74 | — | — | |
| SCHEMBL14842846 | 0.70 | — | — | |
| SCHEMBL27476502 | 0.64 | AKR1C3 (0.30) | — | |
| SCHEMBL4600001 | 0.64 | AKR1C3 (0.44) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL14117526 | 0.64 | AKR1C3 (0.44) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| Acetic Acid SCHEMBL1666951 | 0.63 | CHRNB2 (0.30) | — | |
| SCHEMBL14117545 | 0.62 | ESR2 (0.56) | CYP2C9 | |
| SCHEMBL4600699 | 0.62 | ESR2 (0.56) | CYP2C9 | |
| SCHEMBL10922111 | 0.61 | QDPR (0.40) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6338945-B1 | CONCURRENT SCREENING OF OLIGOPEPTIDE LIBRARIES SYNTHESIZED ON SOLID PHASE SUPPORTS TO ISOLATE BIOACTIVE MOLECULES WHICH ELICIT CYTOLYTIC ACTIVITY | GENZYME CORPORATION | 2002-01-15 | — | — | US | claimed |
| US-12528849-B2 | WT1 HLA class II-binding peptides and compositions and methods comprising same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12195774-B2 | Antidotes to factor XA inhibitors | ALEXION PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240408197-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240368220-A1 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-1997035035-A1 | A METHOD FOR IDENTIFYING CYTOTOXIC T-CELL EPITOPES | NICOLETTE CHARLES (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5650489-A | SOLID PHASE SYNTHESIS OF PEPTIDES, RANDOM SEQUENCES, COMBINATORIAL CHEMISTRY | THE ARIZONA BOARD OF REGENTS (US) | 1997-07-22 | — | — | US | disclosed |
| US-5510240-A | Method of screening a peptide library | THE ARIZONA BOARD OF REGENTS (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0705279-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5470753-A | Peptide sequencing using mass spectrometry | SELECTIDE CORPORATION (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1994028028-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994006017-A1 | PEPTIDE SEQUENCING USING MASS SPECTROMETRY | SELECTIDE CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0542770-A4 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0542770-A1 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | ARIZONA BOARD OF REGENTS a body corporate acting on behalf of Arizona State University (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992000091-A1 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | BIOLIGAND, INC. (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | GRM4 4525/4885CYP1A2 531/4885CYP2C19 374/4885 |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | SERPINC1, F2, F8 | GRM4 4774/4885CYP1A2 1414/4885CYP2C19 1438/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | GRM4 4525/4885CYP1A2 531/4885CYP2C19 374/4885 |
| US-12195774-B2 | Antidotes to factor XA inhibitors | SERPINC1, F2, F8 | GRM4 4774/4885CYP1A2 1414/4885CYP2C19 1438/4885 |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F13B, F2 | GRM4 4658/4885CYP1A2 1966/4885CYP2C19 1928/4885 |
| US-12528849-B2 | WT1 HLA class II-binding peptides and compositions and methods comprising same | MICA, HLA-DRB1, TAP2 | GRM4 4591/4885CYP1A2 4595/4885CYP2C19 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.